

Eric S Lipp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4489200/publications.pdf>

Version: 2024-02-01

115
papers

11,881
citations

159585

30
h-index

64796

79
g-index

116
all docs

116
docs citations

116
times ranked

19690
citing authors

#	ARTICLE	IF	CITATIONS
1	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477.	28.9	3,979
2	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	27.0	2,582
3	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018, 33, 676-689.e3.	16.8	750
4	Frequent <i>ATRX</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012, 3, 709-722.	1.8	532
5	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018, 23, 282-296.e4.	6.4	333
6	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	10.7	307
7	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , 2018, 6, 282-300.e2.	6.2	284
8	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
9	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	6.4	245
10	Mutations in <i>IDH1</i> , <i>IDH2</i> , and in the <i>TERT</i> promoter define clinically distinct subgroups of adult malignant gliomas. <i>Oncotarget</i> , 2014, 5, 1515-1525.	1.8	237
11	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , 2018, 173, 386-399.e12.	28.9	228
12	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , 2018, 23, 297-312.e12.	6.4	205
13	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
14	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7.	6.2	134
15	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. <i>Nature Communications</i> , 2018, 9, 2087.	12.8	124
16	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
17	Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. <i>British Journal of Cancer</i> , 2012, 107, 1481-1487.	6.4	83
18	Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2012, 106, 409-415.	2.9	78

#	ARTICLE	IF	CITATIONS
19	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 352.	12.8	77
20	The genetic landscape of anaplastic astrocytoma. <i>Oncotarget</i> , 2014, 5, 1452-1457.	1.8	69
21	Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 137, 349-356.	2.9	49
22	Morphological and molecular features of astroblastoma, including <i>BRAFV600E</i> mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. <i>Neuro-Oncology</i> , 2017, 19, 31-42.	1.2	45
23	MRP3: a molecular target for human glioblastoma multiforme immunotherapy.. <i>BMC Cancer</i> , 2010, 10, 468.	2.6	44
24	Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1697-1704.	2.5	44
25	Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. <i>Oncologist</i> , 2018, 23, 157-e21.	3.7	44
26	The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts. <i>Clinical Cancer Research</i> , 2020, 26, 5809-5813.	7.0	44
27	Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. <i>Cancer Medicine</i> , 2013, 2, 185-195.	2.8	36
28	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. <i>Acta Neuropathologica</i> , 2020, 139, 277-286.	7.7	36
29	Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. <i>Oncologist</i> , 2015, 20, 727-728.	3.7	32
30	Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. <i>Nuclear Medicine and Biology</i> , 2012, 39, 23-34.	0.6	30
31	Distress persists in long-term brain tumor survivors with glioblastoma multiforme. <i>Journal of Cancer Survivorship</i> , 2008, 2, 269-274.	2.9	26
32	Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. <i>Cancer</i> , 2012, 118, 4759-4767.	4.1	26
33	Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. <i>Oncologist</i> , 2018, 23, 889-e98.	3.7	26
34	Adjunctive perampanel for glioma-associated epilepsy. <i>Epilepsy & Behavior Case Reports</i> , 2018, 10, 114-117.	1.5	26
35	Association between body mass index and mortality in patients with glioblastoma multiforme. <i>Cancer Causes and Control</i> , 2010, 21, 2195-2201.	1.8	24
36	Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2012, 107, 213-221.	2.9	24

#	ARTICLE	IF	CITATIONS
37	A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population. <i>Journal of Neuro-Oncology</i> , 2017, 134, 363-369.	2.9	18
38	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2061-2061.	1.6	17
39	Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated <sc>EGFR</sc>: implications for drug development. <i>Journal of Neurochemistry</i> , 2015, 133, 730-738.	3.9	11
40	Family Appraisal of Caregiving in a Brain Cancer Model. <i>Journal of Hospice and Palliative Nursing</i> , 2009, 11, 60-66.	0.9	10
41	Prognostic marker analysis in pediatric intracranial ependymomas. <i>Journal of Neuro-Oncology</i> , 2015, 122, 255-261.	2.9	10
42	Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice. <i>Health Science Reports</i> , 2019, 2, e114.	1.5	10
43	Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. <i>Supportive Care in Cancer</i> , 2020, 28, 2229-2238.	2.2	9
44	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2068-2068.	1.6	9
45	MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 57-64.	1.7	8
46	Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13526-e13526.	1.6	8
47	Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma. <i>Seminars in Oncology Nursing</i> , 2018, 34, 472-485.	1.5	7
48	Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. <i>Seminars in Oncology Nursing</i> , 2018, 34, 430-442.	1.5	5
49	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. <i>Complementary Therapies in Clinical Practice</i> , 2019, 36, 43-48.	1.7	5
50	Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. <i>Neuro-Oncology Practice</i> , 2021, 8, 299-309.	1.6	5
51	A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2022, 40, e14015-e14015.	1.6	5
52	Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz036.	0.7	4
53	Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. <i>Journal of Neuro-Oncology</i> , 2020, 147, 477-483.	2.9	4
54	CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii37-ii37.	1.2	4

#	ARTICLE	IF	CITATIONS
55	Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.. Journal of Clinical Oncology, 2015, 33, 2034-2034.	1.6	4
56	Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2020, 38, 2566-2566.	1.6	4
57	Consultative Issues in Surgical Neuropathology. American Journal of Clinical Pathology, 2015, 143, 807-811.	0.7	3
58	First in Human Clinical Trial of a Metalloporphyrin Dual Radioprotectant and Radiosensitizer, BMX-001, in Newly Diagnosed High-Grade Glioma Undergoing Concurrent Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2019, 105, E106.	0.8	3
59	Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis. CNS Oncology, 2021, 10, CNS77.	3.0	3
60	Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial. Supportive Care in Cancer, 2022, 30, 3463-3471.	2.2	3
61	CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG). Neuro-Oncology, 2020, 22, ii38-ii38.	1.2	3
62	ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). Neuro-Oncology, 2018, 20, vi9-vi9.	1.2	2
63	HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. Neuro-Oncology, 2018, 20, i93-i93.	1.2	2
64	QOLP-18. A TIME-BASED MODEL OF EARLY PALLIATIVE CARE INTERVENTION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA, A SINGLE INSTITUTION FEASIBILITY STUDY. Neuro-Oncology, 2019, 21, vi201-vi201.	1.2	2
65	Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2012, 30, 2074-2074.	1.6	2
66	Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.. Journal of Clinical Oncology, 2017, 35, e13532-e13532.	1.6	2
67	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. Journal of Clinical Oncology, 2019, 37, 2060-2060.	1.6	2
68	ATCT-01PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG). Neuro-Oncology, 2015, 17, v1.1-v1.	1.2	1
69	ATIM-18. PHASE I DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). Neuro-Oncology, 2016, 18, vi21-vi22.	1.2	1
70	QLIF-05. A SINGLE INSTITUTION'S EXPERIENCE EXPLORING THE ASSOCIATION OF INTEGRATIVE MEDICINE AND SURVIVORSHIP IN GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi202-vi202.	1.2	1
71	ACTR-64. PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology, 2017, 19, vi14-vi14.	1.2	1
72	QOLP-17. REVIEW AND META-ANALYSIS OF NAUSEA AND VOMITING TRIALS FOR MALIGNANT GLIOMAS. Neuro-Oncology, 2018, 20, vi218-vi218.	1.2	1

#	ARTICLE	IF	CITATIONS
73	ACTR-28. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi17-vi17.	1.2	1
74	ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2019, 21, vi6-vi6.	1.2	1
75	QOLP-29. MINDFULNESS MEDITATION PRACTICE IN MALIGNANT GLIOMA PATIENTS THROUGHOUT CONCOMITANT RADIATION AND TEMOZOLOMIDE: A FEASIBILITY STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi204-vi204.	1.2	1
76	Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2027-2027.	1.6	1
77	Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients. <i>Journal of Clinical Oncology</i> , 2015, 33, 9553-9553.	1.6	1
78	Baseline cognitive function to predict survival in patients with glioblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 10125-10125.	1.6	1
79	QOL-19 PROSPECTIVE EVALUATION OF CARDIOPULMONARY FITNESS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING AN ANTI-ANGIOGENIC REGIMEN. <i>Neuro-Oncology</i> , 2015, 17, v192.1-v192.	1.2	0
80	QOL-20 LOW-DOSE NALTREXONE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA: PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED PILOT STUDY. <i>Neuro-Oncology</i> , 2015, 17, v192.2-v192.	1.2	0
81	QOL-21 DIET AND HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN THE PRIMARY BRAIN TUMOR POPULATION. <i>Neuro-Oncology</i> , 2015, 17, v192.3-v192.	1.2	0
82	QLIF-20. A CROSS-SECTIONAL STUDY OF DISTRESS THROUGHOUT THE DISEASE TRAJECTORY IN PRIMARY BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2016, 18, vi160-vi160.	1.2	0
83	NCOG-12. NEUROCOGNITION IN LOW-GRADE GLIOMAS: ASSOCIATIONS WITH MEASURABLE AND PERCEIVED IMPAIRMENTS. <i>Neuro-Oncology</i> , 2016, 18, vi122-vi122.	1.2	0
84	PALL-10. INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS. <i>Neuro-Oncology</i> , 2017, 19, vi170-vi170.	1.2	0
85	PALL-02. PERAMPANEL FOR TREATMENT OF REFRACTORY SEIZURES IN PATIENTS WITH GLIOMAS. <i>Neuro-Oncology</i> , 2017, 19, vi168-vi168.	1.2	0
86	QLIF-22. MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2017, 19, vi206-vi206.	1.2	0
87	QLIF-34. PILOT STUDY TO DESCRIBE THE TRAJECTORY OF SYMPTOMS AND ADAPTIVE STRATEGIES OF ADULTS LIVING WITH LOW GRADE GLIOMAS (LGG). <i>Neuro-Oncology</i> , 2017, 19, vi208-vi209.	1.2	0
88	RARE-36. PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. <i>Neuro-Oncology</i> , 2017, 19, vi217-vi217.	1.2	0
89	GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi112-vi112.	1.2	0
90	HOUT-19. TREATMENT PATTERNS, OUTCOMES, AND PROGNOSTIC INDICATORS IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE SINGLE INSTITUTION ANALYSIS. <i>Neuro-Oncology</i> , 2018, 20, vi117-vi117.	1.2	0

#	ARTICLE	IF	CITATIONS
91	RARE-16. CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF YOUNG ADULTS WITH GLIOBLASTOMA AT DIAGNOSIS. <i>Neuro-Oncology</i> , 2018, 20, vi239-vi239.	1.2	0
92	QOLP-13. PSYCHOSOCIAL DISTRESS IN PATIENTS WITH RECURRENT MENINGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi217-vi217.	1.2	0
93	ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES. <i>Neuro-Oncology</i> , 2018, 20, vi7-vi7.	1.2	0
94	GENE-01. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi102-vi103.	1.2	0
95	ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi8-vi8.	1.2	0
96	HOUT-21. CHARACTERISTICS OF SHORT-TERM SURVIVAL IN PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE ANALYSIS. <i>Neuro-Oncology</i> , 2019, 21, vi116-vi116.	1.2	0
97	INNV-18. THE AVAILABILITY AND ROLE OF CLINICAL PHARMACISTS IN THE AMBULATORY NEURO-ONCOLOGY SETTING: AN INTERNATIONAL SURVEY. <i>Neuro-Oncology</i> , 2019, 21, vi134-vi134.	1.2	0
98	IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii365-iii365.	1.2	0
99	Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631618.	2.8	0
100	An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9521-9521.	1.6	0
101	Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2082-2082.	1.6	0
102	Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2067-2067.	1.6	0
103	Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2015, 33, e13004-e13004.	1.6	0
104	Secondary cancers in long-term survivors of primary glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20616-e20616.	1.6	0
105	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2017, 35, e13533-e13533.	1.6	0
106	Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21636-e21636.	1.6	0
107	Availability and Role of Clinical Pharmacists in Ambulatory Neuro-Oncology. <i>Neuro-Oncology Practice</i> , 2022, 9, 18-23.	1.6	0
108	QOLP-10. A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS. <i>Neuro-Oncology</i> , 2021, 23, vi184-vi185.	1.2	0

#	ARTICLE	IF	CITATIONS
109	QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE. <i>Neuro-Oncology</i> , 2021, 23, vi189-vi189.	1.2	0
110	NCOG-38. CLINICAL CHARACTERISTICS OF LOW GRADE GLIOMA PATIENTS WITH NON-CANONICAL IDH1 AND IDH2 MUTATIONS. <i>Neuro-Oncology</i> , 2020, 22, ii137-ii137.	1.2	0
111	QOLP-20. A FEASIBILITY STUDY UTILIZING MINDFULNESS MEDITATION DURING CONCOMITANT CHEMORADIATION IN MALIGNANT GLIOMA PATIENTS: HEALTH-REPORTED QUALITY OF LIFE (HRQOL) RESULTS. <i>Neuro-Oncology</i> , 2020, 22, ii179-ii179.	1.2	0
112	NCOG-23. PATTERNS OF DISTRESS IN OLDER PATIENTS WITH GLIOBLASTOMA: A FOLLOW-UP TO A SINGLE INSTITUTION CROSS-SECTIONAL STUDY OF DISTRESS IN PRIMARY BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii134-ii134.	1.2	0
113	COVD-25. THE PARADOXICAL EFFECTS OF COVID-19 ON CANCER CARE IN THE NEURO-ONCOLOGY SETTING. <i>Neuro-Oncology</i> , 2020, 22, ii26-ii26.	1.2	0
114	QOLP-05. OLANZAPINE FOR REFRACTORY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii175-ii175.	1.2	0
115	BIOM-20. TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM. <i>Neuro-Oncology</i> , 2021, 23, vi14-vi15.	1.2	0